SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAMPO, Gianluca Calogero
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.214
EU - Europa 3.120
AS - Asia 1.918
SA - Sud America 13
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 3
Totale 20.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.197
CN - Cina 1.253
IT - Italia 783
UA - Ucraina 610
TR - Turchia 475
DE - Germania 425
GB - Regno Unito 347
PL - Polonia 289
SE - Svezia 272
FI - Finlandia 136
FR - Francia 123
BE - Belgio 50
HK - Hong Kong 49
VN - Vietnam 40
IN - India 30
CA - Canada 15
KR - Corea 14
RU - Federazione Russa 12
IR - Iran 11
DK - Danimarca 10
CH - Svizzera 9
AU - Australia 8
JP - Giappone 8
IE - Irlanda 7
ES - Italia 6
PK - Pakistan 6
RO - Romania 6
CY - Cipro 5
MK - Macedonia 5
PT - Portogallo 5
SG - Singapore 5
BR - Brasile 4
CO - Colombia 4
EU - Europa 4
TH - Thailandia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
HR - Croazia 3
NL - Olanda 3
NZ - Nuova Zelanda 3
AT - Austria 2
GR - Grecia 2
HU - Ungheria 2
ID - Indonesia 2
IQ - Iraq 2
LT - Lituania 2
MX - Messico 2
MY - Malesia 2
PH - Filippine 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
BD - Bangladesh 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
IM - Isola di Man 1
KW - Kuwait 1
LU - Lussemburgo 1
MD - Moldavia 1
NO - Norvegia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 20.283
Salva come PNG Salva come JPEG
Città #
Fairfield 2.300
Woodbridge 1.810
Ashburn 1.288
Houston 1.170
Chandler 1.030
Seattle 936
Wilmington 849
Ann Arbor 806
Cambridge 764
Jacksonville 757
Izmir 338
Beijing 326
Princeton 324
Warsaw 285
Nanjing 267
New York 258
San Diego 205
Ferrara 197
Shanghai 179
Milan 158
Boardman 126
Bremen 79
Shenyang 74
Nanchang 71
Falls Church 63
Redwood City 61
Jiaxing 51
Washington 49
Brussels 48
Tianjin 48
Bologna 46
Mountain View 44
London 41
Hebei 40
Hong Kong 40
Dong Ket 39
Changsha 38
Addison 34
San Mateo 34
Norwalk 32
Los Angeles 27
Jinan 26
Chicago 23
Des Moines 23
Kunming 23
Orange 22
Augusta 20
Redmond 20
Ningbo 19
Tappahannock 16
Zhengzhou 16
Auburn Hills 15
Dearborn 15
Helsinki 15
Taizhou 13
Leawood 12
Monmouth Junction 12
Napoli 12
Rimini 12
Hounslow 10
Indiana 10
Kilburn 10
Guangzhou 9
Hangzhou 9
Ferrara di Monte Baldo 8
Lanzhou 8
Ardabil 7
Naples 7
Dublin 6
Lugo 6
Montreal 6
Odense 6
Padova 6
Phoenix 6
Poggio Renatico 6
Rovigo 6
Arezzo 5
Castel Frentano 5
Changchun 5
Chiswick 5
Detroit 5
Frankfurt am Main 5
Haikou 5
Imola 5
Mumbai 5
Nicosia 5
Paris 5
Rome 5
San Francisco 5
Vicenza 5
Civitanova Marche 4
Florence 4
Lappeenranta 4
Philadelphia 4
Pune 4
Romainville 4
Rovereto 4
Somma Vesuviana 4
Southwark 4
Taipei 4
Totale 15.882
Salva come PNG Salva come JPEG
Nome #
Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): Rationale and design of a randomized clinical trial 243
Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease 178
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 152
Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C-ring conformation 151
Kounis-Zavras syndrome presenting with ventricular arrhythmias and cardiogenic shock 140
Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury 140
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 138
The use of nutraceuticals to counteract atherosclerosis: The role of the Notch pathway 137
Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review 137
Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. 134
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study 134
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial 131
Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention 130
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 129
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial 129
Poor response to clopidogrel: current and future options for its management 129
Fractional flow reserve: Current applications and overview of the available data 128
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 128
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 128
Notch Signaling Regulates Immune Responses in Atherosclerosis 128
Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention 127
Fractional flow reserve evaluation and chronic kidney disease: Analysis from a multicenter Italian registry (the FREAK study) 126
Prognostic Impact of Hospital Readmissions After Primary Percutaneous Coronary Intervention 125
Short Physical Performance Battery and all-cause mortality: Systematic review and meta-analysis 125
Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis 124
Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial 124
Reperfusion Damage - A Story of Success, Failure, and Hope 123
Discovery of Novel 1,3,8-Triazaspiro[4.5]decane Derivatives That Target the c Subunit of F1/FO-Adenosine Triphosphate (ATP) Synthase for the Treatment of Reperfusion Damage in Myocardial Infarction 123
SERPINA1 Gene Promoter Is Differentially Methylated in Peripheral Blood Mononuclear Cells of Pregnant Women 123
Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting 122
Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study) 120
Can we improve myocardial protection during ischaemic injury? 120
A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score on 1-Year Clinical Outcomes in 6,508 Patients Enrolled in Contemporary Coronary Stent Trials 119
The in vitro effects of verbascoside on human platelet aggregation 118
Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting 118
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 118
Mechanistic role of mPTP in ischemia-reperfusion injury 117
Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis 115
Ticagrelor improves endothelial function by decreasing circulating Epidermal Growth Factor (EGF) 115
A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial 113
Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention 113
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial 113
Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial 112
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials 111
Grip strength predicts cardiac adverse events in patients with cardiac disorders: An individual patient pooled meta-analysis 111
The assessment of scales of frailty and physical performance improves prediction of major adverse cardiac events in older adults with acute coronary syndrome 111
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 110
Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction 109
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 109
Characterization of Dermal Stem Cells of Diabetic Patients 109
Impact of COPD on Long-term Outcome After ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention 109
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 109
Patient selection to enhance the long-term benefit of first generation drug-eluting stents for coronary revascularisation procedures. Insights from a large multicentre registry 109
A Strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. 108
Relevance of gender in patients with acute myocardial infarction undergoing coronary interventions 108
Exercise Intervention to Improve Functional Capacity in Older Adults After Acute Coronary Syndrome 108
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study 107
Specific properties and effect of perindopril in controlling the renin-angiotensin system. 106
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients 106
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 106
Tissue Factor and Coagulation Factor VII Levels during Acute Myocardial Infarction Contribute to Predict Mortality and re-infarction. 105
Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the registro regionale angioplastiche Emilia-Romagna registry) 105
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates 105
Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: Systematic review and meta-analysis of randomized clinical trials 105
Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients with ST-Segment-Elevation Myocardial Infarction and Multivessel Disease 105
Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes 104
Poor responsiveness to clopidogrel. Drug-specific or class-effect? 104
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry 104
Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated with Second-Generation Drug-Eluting Stents 104
CHA2DS2-VASc risk factors as predictors of stroke after acute coronary syndrome: A systematic review and meta-analysis 104
Operator, Drug or Device: Who Will Break Down Acute Stent Thrombosis 104
Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study 103
Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study 102
Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention 102
Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress 102
Fractional flow reserve implementation in daily clinical practice: A European survey 102
The Mitochondrial Permeability Transition Pore 102
Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. 101
Different clinical models of CD34 plus cells mobilization in patients with cardiovascular disease 101
Long-term outcomes with cobalt-chromium bare-metal vs. drug-eluting stents: the REgistro regionale AngiopLastiche dell'Emilia-Romagna registry 100
Nutritional status and all-cause mortality in older adults with acute coronary syndrome 100
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. 99
New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios 99
A Prospective Evaluation of a Standardized Strategy for the Use of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in ST-Segment Elevation Myocardial Infarction: Rationale and Design of the BVS STEMI STRATEGY-IT Study 98
Incidence and outcome of high on-treatment platelet reactivity in patients with non-st elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [verifynow and inhibition of platelet reactivity] study) 98
Same-day transfer for the invasive strategy of patients with non-ST-segment elevation acute coronary syndrome admitted to spoke hospitals: Data from the Emilia-Romagna Regional Network 97
Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system 96
Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study 96
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: A systematic review and meta-analysis 96
Specific and selective I-f inhibition: expected clinical benefits from pure heart rate reduction in coronary patients 95
Coronary artery surgery versus percutaneous coronary intervention in octogenarians: long-term results 95
Dual Antiplatelet Therapy in Patients with Glucose-6-Phosphate Dehydrogenase Deficiency undergoing PCI with Drug-Eluting Stents. 95
Tissue factor and coagulation factor VII levels during AMI: association with genotype and adverse events 94
null 94
Impact of culprit plaque and atherothrombotic components on incomplete stent apposition in patients with ST-elevation myocardial infarction treated with Everolimus-eluting stents-an OCTAVIA Substudy 94
The impact of the 3-year ABSORB II trial results on my clinical practice: An Italian survey 94
Transradial coronary catheterization and intervention across the whole spectrum of Allen test results 93
Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study 93
Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter “real-world” registry 92
BRS implantation in long lesions requiring device overlapping: Myth or reality? 92
Totale 11.417
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 903
Totale 105.026
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.010 0 0 0 0 0 0 0 0 0 446 606 958
2019/20204.766 657 214 183 662 340 552 470 471 431 432 225 129
2020/20213.825 196 258 193 488 231 296 166 496 174 540 535 252
2021/20223.141 272 287 207 147 138 163 193 195 141 238 336 824
2022/20232.773 338 124 141 234 405 394 176 251 360 71 190 89
2023/20241.961 168 292 130 91 214 484 131 279 68 104 0 0
Totale 21.154